Mercury Biopharmaceutical Corporation
6932
Rank in Stocks
#21205
Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury... Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury Biopharmaceutical Corporation is dedicated to creating innovative pharmaceutical solutions for medical conditions currently lacking adequate treatment options. A cornerstone of their strategy is the proprietary StackDose platform, an advanced drug development system designed to formulate novel medication delivery methods. This platform facilitates precisely timed drug release, targeted absorption at specific locations within the body, and flexible dosage modifications. The primary objective of StackDose is to significantly boost the bioavailability of active pharmaceutical ingredients, leading to a reduction in required drug dosages and fewer adverse effects. Their development pipeline currently addresses a variety of ailments, such as erectile dysfunction, pulmonary hypertension, sleep disturbances, benign prostatic hyperplasia, angina, migraines, hypertension, and pain management.
Share Price
$0.16796937
Last synced: 2026-11-10
Market Cap
$71.83M
Change (1 day)
5.35%
Change (1 year)
-43.23%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Mercury Biopharmaceutical Corporation (6932)
Category
Healthcare
Operating Margin for Mercury Biopharmaceutical Corporation (6932)
Operating Margin as of November 2026 TTM: 0.00%
According to Mercury Biopharmaceutical Corporation's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Mercury Biopharmaceutical Corporation from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -1,088.90% | -75.38% |
| 2023 | -4,423.04% | 284.24% |
| 2022 | -1,151.12% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | - |
DE
|
|
| 19.68% | - |
DE
|
|
| 13.26% | - |
JP
|
|
| 17.08% | - |
CH
|
|
| 14.92% | - |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Mercury Biopharmaceutical Corporation's operating margin
What was Mercury Biopharmaceutical Corporation's operating margin in 2025?
In 2025, Mercury Biopharmaceutical Corporation's operating margin was 0.00%, compared with -1,088.90% in 2024.
How has Mercury Biopharmaceutical Corporation's operating margin changed since 2020?
From 2020 to 2025, Mercury Biopharmaceutical Corporation's operating margin was highest in 2025 (0.00%) and lowest in 2023 (-4,423.04%).
How does Mercury Biopharmaceutical Corporation's operating margin compare with similar companies?
Mercury Biopharmaceutical Corporation's operating margin (0.00%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.